A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

Inclusion criteria: All parts * Previously-identified activating Kirsten rat sarcoma viral oncogene homologue (KRAS) mutation in tumour tissue or blood prior to screening * At least one target lesion that can be measured per Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate organ function * Age ≥18 years of age, or over the legal age of consent as required by local legislation. * Signed and dated written informed consent in accordance with GCP and local legislation prior to admission to the trial. * Women of childbearing potential who are not surgically sterilized must have a negative serum pregnancy test completed during the Screening period * Further inclusion criteria apply Monotherapy and combination therapy dose escalation and monotherapy dose confirmation part \- Documented disease progression despite appropriate prior standard therapies or for whom no standard therapy exists for their tumour type and disease stage Combination dose confirmation and expansion cohort * Pathologically confirmed diagnosis of adenocarcinoma of the lung. Patients with mixed histology are eligible if adenocarcinoma is the predominant histology. * Locally advanced stage IIIb or metastatic stage IV Non-small cell lung cancer (NSCLC) * Patients must have received both chemotherapy and immunotherapy Exclusion criteria: All parts * Previous anticancer chemotherapy within 3 weeks of the fi…